HOME > Public Health News > A single pill could treat Alzheimer's, Parkinson's AND multiple sclerosis :: Manufacturer of Eleotin – Eastwoodcompanies.com

PUBLIC HEALTH NEWS

Reg. Date : 2012.07.25 11:10
A single pill could treat Alzheimer's, Parkinson's AND multiple sclerosis
Views : 2621 

One pill with the potential to treat conditions including Alzheimer’s disease, multiple sclerosis and strokes has been unveiled by scientists.


Given early enough, it may even be able to stop full-blown Alzheimer’s from taking hold.


It works by dampening down the inflammation thought to be at least partly to blame for many degenerative brain conditions, as well damage caused by head injuries and strokes.


Animal tests have been encouraging and the pill has been given to humans for the first time, although the results have yet to be released.


Early results from animal studies suggest it could be effective against a plethora of devastating brain conditions.


They include Alzheimer's and Parkinson's disease, multiple sclerosis (MS), motor neurone disease, frontotemporal dementia, and complications from traumatic brain injury.


Two of the drugs, known as MW151 and MW189, have been patented by US scientists at Northwestern University in Chicago.


They work by blocking excess production of damaging immune system signalling molecules called pro-inflammatory cytokines.


New research published today in the Journal of Neuroscience showed how early treatment with MW151 prevented the development of full-blown Alzheimer's in laboratory mice.


Scientists say the drugs offer a completely different approach to treating the disease to others currently being tested.


These target the accumulation of beta amyloid protein deposits in the brain which are a key feature of Alzheimer's.


In contrast the new drugs are designed to stop inflammation disrupting wiring in the brain and killing neurons.


Pro-inflammatory cytokines cause the synapses, the connections between brain cells, to misfire. Eventually the whole organisation of the brain falls into disarray, like a failing computer, and neurons die.


'In Alzheimer's disease, many people now view the progression from mild cognitive impairment to full-blown Alzheimer's as an indication of malfunctioning synapses, the pathways that allow neurons to talk to each other,' said Professor Martin Watterson, one of the study leaders at Northwestern University's Feinberg School.


'High levels of pro-inflammatory cytokines can contribute to synaptic malfunction.'


Mice genetically engineered to develop Alzheimer's were given MW151 three times a week starting at six months of age. A comparable stage in humans would be when a patient begins to experience mild mental decline.


At 11 months, by which time the mice should have developed full-blown Alzheimer's, cytokine levels in the brains of the animals were found to be back to normal. Their synapses were also working normally.


Untreated mice had abnormally high brain levels of cytokines and their synapses were misfiring.


Co-author Dr Linda Van Eldik, director of the Sanders-Brown Centre on Aging at the University of Kentucky, said: 'The drug protected against the damage associated with learning and memory impairment. Giving this drug before Alzheimer's memory changes are at a late stage may be a promising future approach to therapy.'


Harmful inflammation also plays a role in a wide range of other neurodegenerative disorders, raising the prospect of using the drug to treat many different conditions.


Earlier tests on mice showed that MW151 reduced the severity of a disease similar to MS in humans that strips nerve fibres of their insulating myelin covering.


In other mouse experiments, the drug prevented a surge of pro-inflammatory cytokines after traumatic brain injury.


'If you took a drug like this early on after traumatic brain injury or even a stroke, you could possibly prevent the long-term complications of that injury including the risk of seizures, cognitive impairment, and, perhaps, mental health issues,' said Professor Mark Wainright, also from Northwestern's Feinberg School

.

Parkinson's, non-Alzheimer's dementia and motor neurone disease were other conditions that could potentially be tackled using the new approach.


A key advantage of the drug is that it can be swallowed as a pill, rather than being injected. It easily crosses the 'blood brain barrier', a physical and molecular fortress wall that stops toxic molecules entering the brain.


Results are yet to be released from the first Phase I trial assessing the drug's safety in human patients.

This is the first step in winning clinical approval for a new treatment.


 
Original Post from: http://www.dailymail.co.uk/health/article-2178306/A-single-pill-treat-Alzheimers-Parkinsons-AND-multiple-sclerosis.html

Total 125
No. SUBJECT DATE VIEW
125 An A+ Brain!  10-11 1823
124 Turmeric Improves Blood Glucose in Type 2 Diabetes  09-10 2427
123 4 Healthy Habits Stop Cancer, Diabetes, and Heart Disease   07-30 3157
122 Diabetes mellitus may boost pancreatic cancer risk  07-30 2517
121 Like curry? It could help cut your diabetes risk  07-30 2688
120 Diabetes News: Native Americans Ate 16 Times More Fiber than People Today   07-26 2551
119 Exercise Still Cuts Diabetes Risk  07-26 2547
118 Study Suggests That High Doses Of Vitamin D May Prevent Bone Fractures  07-25 2175
117 Women with diabetes more likely to experience sexual dissatisfaction   07-25 2569
116 Weight loss boosts sex life of obese men: study  07-25 2491
115 Best exercise to avoid diabetes study  07-25 2731
114 Diet and Exercise Help With the Weighty Issues of Pregnancy  07-25 2669
113 Vitamin-mineral mix helps slow impact of macular degeneration  07-25 2854
112 A single pill could treat Alzheimer's, Parkinson's AND multiple sclerosis  07-25 2621
111 Iron Deficiency in Children Due to a Certain Combination of Risk Factors  07-25 3467
110 Sex Hormones Linked to Metabolism, Genetic Study   07-24 2558
109 Fig Leaves Used to Treat Diabetes   07-24 2537
108 Cheese Will Make You Happy, May Also Lower Diabetes Risk  07-24 2737
107 FDA approves weight-loss drug  07-23 2414
106 10 Common Food Combinations That Wreak Havoc on Your Health  07-23 4963
 
 
 1  2  3  4  5  6  7  
    Eastwood Bio-Medical Research Inc. Unit 1130-4871 Shell Road Richmond, B.C. Canada, V6X 3Z6
Tel: 604.247.2100 or 1.888.669.4372      Email: info@eastwoodcos.com
Copyright© 2011 Eastwood Companies